Literature DB >> 9364683

Comparative efficacy of a Coxiella burnetii chloroform:methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol.

D M Waag1, M J England, M L Pitt.   

Abstract

Q fever is an acute and self-limited febrile illness caused by the obligate intracellular bacterium Coxiella burnetii. While phase I cellular Q fever vaccines are efficacious in humans, vaccination of immune individuals may result in sterile abscesses and granulomas. The chloroform:methanol residue vaccine (CMR) was developed as a safer alternative. The efficacy of a licensed phase I cellular vaccine (Q-Vax) was compared with that of CMR vaccine in A/J mice and Hartley guinea pigs challenged with virulent phase I C. burnetii by aerosol. Both vaccines were efficacious. The CMR vaccine dose required to protect 50% of mice (PD50) against lethal aerosol challenge (11 LD50) was one-third of the Q-Vax dose. However, the PD50 for CMR was four times the Q-Vax dose in guinea pigs challenged by aerosol (60 LD50). It was concluded that CMR is an efficacious alternative to cellular Q fever vaccines for the prevention of Q fever.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364683     DOI: 10.1016/s0264-410x(97)00107-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Cloning and porin activity of the major outer membrane protein P1 from Coxiella burnetii.

Authors:  Sunita Varghees; Kati Kiss; Giovanni Frans; Orit Braha; James E Samuel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

2.  The attenuated nine mile phase II clone 4/RSA439 strain of Coxiella burnetii is highly virulent for severe combined immunodeficient (SCID) mice.

Authors:  Aminul Islam; Michelle Lockhart; John Stenos; Stephen Graves
Journal:  Am J Trop Med Hyg       Date:  2013-08-19       Impact factor: 2.345

3.  Clinical and pathologic changes in a guinea pig aerosol challenge model of acute Q fever.

Authors:  K E Russell-Lodrigue; G Q Zhang; D N McMurray; J E Samuel
Journal:  Infect Immun       Date:  2006-11       Impact factor: 3.441

4.  Identification of Coxiella burnetii CD8+ T-Cell Epitopes and Delivery by Attenuated Listeria monocytogenes as a Vaccine Vector in a C57BL/6 Mouse Model.

Authors:  Xiaolu Xiong; Jun Jiao; Anthony E Gregory; Pengcheng Wang; Yujing Bi; Xiaoyi Wang; Yongqiang Jiang; Bohai Wen; Daniel A Portnoy; James E Samuel; Chen Chen
Journal:  J Infect Dis       Date:  2017-05-15       Impact factor: 5.226

Review 5.  A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.

Authors:  Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio
Journal:  Biomedicines       Date:  2022-08-22

Review 6.  Immunogenicity and Reactogenicity in Q Fever Vaccine Development.

Authors:  Alycia P Fratzke; Erin J van Schaik; James E Samuel
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

7.  Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii.

Authors:  David M Waag; Marilyn J England; Christopher R Bolt; Jim C Williams
Journal:  Clin Vaccine Immunol       Date:  2008-08-13

8.  Biodefense-driven murine model of pneumonic melioidosis.

Authors:  J A Jeddeloh; D L Fritz; D M Waag; J M Hartings; G P Andrews
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

9.  Immunoreactive Coxiella burnetii Nine Mile proteins separated by 2D electrophoresis and identified by tandem mass spectrometry.

Authors:  James R Deringer; Chen Chen; James E Samuel; Wendy C Brown
Journal:  Microbiology (Reading)       Date:  2010-10-28       Impact factor: 2.777

Review 10.  Changing epidemiology of Q fever in Germany, 1947-1999.

Authors:  W Hellenbrand; T Breuer; L Petersen
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.